New equity financing would provide the Company sufficient financial visibility to execute its strategic plan and achieve profitability The...
U.S. sales surge +31% at constant exchange rates, with continued acceleration over the year Commercial momentum highlighted by a doubling of U.S....
Capital increase of €5m to €8m through a private placement planned for the first half of November via the issuance of shares with attached warrants...
A large majority of creditors and shareholders have voted in favor of the draft safeguard plan This plan includes a 70% reduction in debt,...
32% Reduction in H1 2025 Current Operating Loss excluding [Non-cash] Share-based Payments Improvement Reflects Strict Expense Control...
Reduction of the Company's debt from €40 million to €12 million, spread over 10 years Capital increase of at least €5 million post-plan adoption,...
Paris, Boston and Sydney, September 18, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT) and Endotherapeutics, today...
Shareholders, holders of securities giving access to the capital, and creditors of Mauna Kea Technologies convened into classes of affected parties...
New letter published by the AFS highlights Cellvizio’s superiority to conventional tools for detecting pre-cancerous tissue and dysplasia Paris and...
On Constant Currency Basis (CER), U.S. sales up +17% Y/Y in H1 and +23% in Q2 Record U.S. sales productivity despite ongoing safeguard...
Leveraging strong momentum for the CellTolerance® application, Mauna Kea Technologies is expanding into new geographies with high growth potential ...
14th U.S. AI patent awarded complementing a comprehensive portfolio of AI-related intellectual property An ecosystem built around the...
